Forty Seven bucks the trend
Tackling the CD47 pathway has seen off several industry players, but Forty Seven continues proudly flying the flag.
Internal FDA documents reveal a familiar story for Sarepta
The unexpected approval of Vyondys 53 followed an FDA power struggle, and turned on a vague commitment from Sarepta, it has emerged.
Nektar’s clearing event clears away $500m
As a US adcom gives the strongest possible indication that oxycodegol won’t be approved, Nektar’s valuation loses 11%.
Morphosys gets a major tafasitamab endorsement
Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.
Astra and Acasti throw the Amarin bulls more fodder
Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.
Clinical win gives Verona a kiss of life
For Verona’s long-suffering shareholders today brought an unexpected clinical success with ensifentrine.
Blueprint beats Deciphera to the punch
In the battle between two Kit/PDGFRα kinase inhibitors first blood goes to Blueprint’s avapritinib.
Lilly jumps the gun with Dermira deal
The $1.1bn that Lilly is paying for lebrikizumab looks low ball, but competing against Dupixent will not come cheap. And then there are the Roche payments.
Verastem plays the Kras card
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.